Valneva SE (EPA:VLA)
3.720
+0.062 (1.69%)
At close: Nov 10, 2025
Valneva SE Revenue
Valneva SE had revenue of 48.33M EUR in the quarter ending June 30, 2025, with 26.98% growth. This brings the company's revenue in the last twelve months to 196.33M, up 25.47% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
196.33M
Revenue Growth
+25.47%
P/S Ratio
3.20
Revenue / Employee
280.47K
Employees
713
Market Cap
628.19M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 45.93B |
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| bioMérieux | 4.12B |
| Ipsen | 3.76B |
| Sartorius Stedim Biotech | 2.95B |
Valneva SE News
- 6 days ago - Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate - GlobeNewsWire
- 14 days ago - Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences - GlobeNewsWire
- 23 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 4 weeks ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 4 weeks ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 5 weeks ago - Valneva SE (VALN) Lowers 2025 Sales Forecast Amid Vaccine Setback - GuruFocus
- 5 weeks ago - Valneva lowers 2025 financial outlook due to loss of Ixchiq vaccine marketing - Seeking Alpha
- 5 weeks ago - Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates - GlobeNewsWire